Matches in Wikidata for { <http://www.wikidata.org/entity/Q64187242> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q64187242 description "clinical trial" @default.
- Q64187242 description "ensayu clínicu" @default.
- Q64187242 description "klinisch onderzoek" @default.
- Q64187242 description "клінічне випробування" @default.
- Q64187242 name "Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)" @default.
- Q64187242 type Item @default.
- Q64187242 label "Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)" @default.
- Q64187242 prefLabel "Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)" @default.
- Q64187242 P1132 Q64187242-DE7B7F88-6F37-4D1F-BA38-83D8DA2D80F2 @default.
- Q64187242 P1476 Q64187242-987D32BF-EF4B-4FDE-B6A6-8C7BDBAB782A @default.
- Q64187242 P17 Q64187242-016ED97C-4AA1-42BC-9CBA-97D83760F1B2 @default.
- Q64187242 P17 Q64187242-019D7A0D-551D-46E6-AE69-55B942A9AA88 @default.
- Q64187242 P17 Q64187242-0E4B51AC-B77A-43AA-A45F-7D1DBC3D3E31 @default.
- Q64187242 P17 Q64187242-13C07F02-FF53-48EC-9E4B-B760599D5E37 @default.
- Q64187242 P17 Q64187242-1E144A2B-EDA7-4DE0-9299-B2771D9A71ED @default.
- Q64187242 P17 Q64187242-24D5F1DB-21E4-4064-8EB3-4103BF56D49F @default.
- Q64187242 P17 Q64187242-52F7376A-1B63-474E-9D55-17B17E65E757 @default.
- Q64187242 P17 Q64187242-84D05E83-2FCE-4163-8CD0-ED84F3AB9039 @default.
- Q64187242 P17 Q64187242-8504294A-B72C-444E-93BB-923155E4CC64 @default.
- Q64187242 P17 Q64187242-855AA869-D4DB-4443-B5E9-85701C12DB22 @default.
- Q64187242 P17 Q64187242-8D534D7C-FF55-4386-BE4A-08CC051AF803 @default.
- Q64187242 P17 Q64187242-90D0602E-734D-4F46-AE55-817C322890AA @default.
- Q64187242 P17 Q64187242-AE54884F-1AD3-41A2-B892-3B93AF189B8C @default.
- Q64187242 P17 Q64187242-CB58A52B-D552-4E51-B115-CDCDB791D2A3 @default.
- Q64187242 P17 Q64187242-F211574A-170C-4AA7-8F19-3269AC558912 @default.
- Q64187242 P2899 Q64187242-875A6A34-0D96-4727-8972-D0EF010475D3 @default.
- Q64187242 P3098 Q64187242-3F0D5D2F-51DF-4DF5-955F-BFEAE42DCC0E @default.
- Q64187242 P31 Q64187242-83380CAD-16D0-473E-B289-32061F451EF0 @default.
- Q64187242 P580 Q64187242-0D736249-5681-4E52-A9D8-9B104FE5F382 @default.
- Q64187242 P582 Q64187242-B923070D-6CAF-402C-87C6-C889CDEEEF44 @default.
- Q64187242 P6099 Q64187242-9A0229AA-4F98-47E9-A483-8A564B531980 @default.
- Q64187242 P8363 Q64187242-E5ED752A-B204-4AF5-8664-83DF9DCDDB2F @default.
- Q64187242 P1132 "+998" @default.
- Q64187242 P1476 "A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies" @default.
- Q64187242 P17 Q142 @default.
- Q64187242 P17 Q16 @default.
- Q64187242 P17 Q183 @default.
- Q64187242 P17 Q214 @default.
- Q64187242 P17 Q215 @default.
- Q64187242 P17 Q218 @default.
- Q64187242 P17 Q28 @default.
- Q64187242 P17 Q29 @default.
- Q64187242 P17 Q31 @default.
- Q64187242 P17 Q33 @default.
- Q64187242 P17 Q35 @default.
- Q64187242 P17 Q36 @default.
- Q64187242 P17 Q39 @default.
- Q64187242 P17 Q40 @default.
- Q64187242 P17 Q41 @default.
- Q64187242 P2899 "+18" @default.
- Q64187242 P3098 "NCT02476006" @default.
- Q64187242 P31 Q30612 @default.
- Q64187242 P580 "2015-06-23T00:00:00Z" @default.
- Q64187242 P582 "2019-04-12T00:00:00Z" @default.
- Q64187242 P6099 Q42824827 @default.
- Q64187242 P8363 Q78089383 @default.